Cohance Lifesciences Limited (NSE:COHANCE)
India · Delayed Price · Currency is INR 472.45
+8.35 (1.80%)
Nov 12, 2026, 3:30 PM IST
Cohance Lifesciences Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Cohance Lifesciences stock has a consensus rating of "Hold" and an average price target of ₹508.00. The average 1-year stock price forecast is 7.52% higher than the current stock price, while the lowest is ₹280.00 (-40.73%) and the highest is ₹1,150 (+143.41%).
Price Target: ₹508.00 (+7.52%)
Analyst Consensus: Hold
Price Target
Chart* Price targets were last updated on Aug 6, 2026.
Analyst Ratings
The average analyst rating for Cohance Lifesciences stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 2 | 2 | 2 | 2 | 2 | 1 |
| Strong Sell | 2 | 2 | 2 | 2 | 2 | 3 |
| Total | 9 | 9 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Sell Maintains ₹300.00 → ₹350.00 | Sell | Maintains | ₹300.00 → ₹350.00 | -25.92% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
22.60B
from 22.69B
Decreased by -0.36%
Revenue Next Year
28.74B
from 22.60B
Increased by 27.12%
EPS This Year
5.00
from 5.24
Decreased by -4.57%
EPS Next Year
8.87
from 5.00
Increased by 77.51%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.